Physician profile
Dana Meade
NPI 1780337162
$2,650.01
in general payments reported to CMS, 2019-2025
20 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.77 · 2023: $220 · 2024: $645 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880 · Travel and Lodging: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.02 |
| Travel and Lodging | $699.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $793.58 | 2025 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $304.03 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $168.38 | 2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $153.31 | 2023-2025 | Brilinta, Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.30 | 2022-2025 | Jardiance |
| Heartflow, INC. | $137.65 | 2025 | |
| Pfizer INC. | $128.43 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.57 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $118.01 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $114.79 | 2025 | Onpattro, Amvuttra |
| Cvrx, INC. | $101.01 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $93.86 | 2022-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $61.00 | 2023-2024 | Verquvo |
| Amgen INC. | $45.54 | 2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $39.65 | 2023-2024 | Opsumit, Uptravi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.69 | 2022-2024 | Xarelto |
| Scpharmaceuticals INC. | $30.71 | 2024 | |
| Thrombolex, INC. | $25.35 | 2025 | Bashir Endovascular Catheter |
| Philips North America LLC | $21.67 | 2025 | Ecc Solutions |
| Boston Scientific Corporation | $15.48 | 2025 | Ams 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.